Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis

The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres. This trial specifically targets patients diagnosed with hepatocellular carcinoma accompanied by localized portal vein tumor thrombosis (Vp1-Vp3) and who maintain good liver function.

Trial Details

NCT ID
NCT06166576
Phase
PHASE2
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Ablative radioembolization
Locations (sample)
  • Ilsan, Gyeonggi-do, South Korea
  • Seongnam-si, Gyeonggi-do, South Korea|37.43861,127.13778
  • Seoul, Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Adults aged 18 and over
  • Patients diagnosed with unilobar hepatocellular carcinoma, either histologically and/or radiologically (LI-RADS 4 or 5)
  • Patients with at least one measurable lesion greater than 10 mm on dynamic contrast-enhanced CT or MRI
  • Patients with localized portal vein invasion limited in one lobe (Vp1-3) on dynamic contrast-enhanced CT or MRI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →